Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study

Background This research assesses whether multi-year treatment with antipsychotic medications reduces or eliminates psychosis in schizophrenia. It provides 20 years of longitudinal data on the frequency and severity of psychotic activity in samples of schizophrenia patients (SZ) treated versus those not treated with antipsychotic medications. Method A total of 139 early young schizophrenia and mood-disordered patients were assessed at index hospitalization and then reassessed six times over 20 years for psychosis and other major variables. Results At each follow-up assessment over the 20 years, a surprisingly high percentage of SZ treated with antipsychotics longitudinally had psychotic activity. More than 70% of SZ continuously prescribed antipsychotics experienced psychotic activity at four or more of six follow-up assessments over 20 years. Longitudinally, SZ not prescribed antipsychotics showed significantly less psychotic activity than those prescribed antipsychotics (p < 0.05). Conclusions The 20-year data indicate that, longitudinally, after the first few years, antipsychotic medications do not eliminate or reduce the frequency of psychosis in schizophrenia, or reduce the severity of post-acute psychosis, although it is difficult to reach unambiguous conclusions about the efficacy of treatment in purely naturalistic or observational research. Longitudinally, on the basis of their psychotic activity and the disruption of functioning, the condition of the majority of SZ prescribed antipsychotics for multiple years would raise questions as to how many of them are truly in remission.

[1]  S. Dursun,et al.  Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients , 2012, Therapeutic advances in psychopharmacology.

[2]  P. McGorry,et al.  Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. , 2013, JAMA psychiatry.

[3]  M. Harrow,et al.  Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? , 1994, Schizophrenia bulletin.

[4]  M. Bleuler The schizophrenic disorders: Long-term patient and family studies , 1978 .

[5]  J. Endicott,et al.  A diagnostic interview: the schedule for affective disorders and schizophrenia. , 1978, Archives of general psychiatry.

[6]  V. Goghari,et al.  A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders , 2012, Psychological Medicine.

[7]  D. Quinlan,et al.  Disordered Thinking and Schizophrenic Psychopathology , 1985 .

[8]  I. Glick,et al.  A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.

[9]  Ronald Pierson,et al.  Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. , 2011, Archives of general psychiatry.

[10]  P. Hutton,et al.  Antipsychotics: is it time to introduce patient choice? , 2012, British Journal of Psychiatry.

[11]  M. Harrow,et al.  Psychotic unipolar depression at follow-up: factors related to psychosis in the affective disorders. , 1994, The American journal of psychiatry.

[12]  M. Harrow,et al.  Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? , 2013, Schizophrenia bulletin.

[13]  S. Silverstein,et al.  A scientific agenda for the concept of recovery as it applies to schizophrenia. , 2008, Clinical psychology review.

[14]  A. Jablensky,et al.  What Did the WHO Studies Really Find? , 2007, Schizophrenia bulletin.

[15]  D. Wiersma,et al.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. , 2013, JAMA psychiatry.

[16]  L. Ciompi,et al.  Soteria Berne: an innovative milieu therapeutic approach to acute schizophrenia based on the concept of affect-logic. , 2004, World psychiatry : official journal of the World Psychiatric Association.

[17]  D. Healy,et al.  Neuroleptic discontinuation syndromes , 1998, Journal of psychopharmacology.

[18]  D. Penn,et al.  Psychosocial treatments for schizophrenia. , 2013, Annual review of clinical psychology.

[19]  R. Rosenheck,et al.  Compliance with medication regimens for mental and physical disorders. , 1998, Psychiatric services.

[20]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[21]  J. Moncrieff The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment , 2007 .

[22]  Robin M. Murray,et al.  Schizophrenia: From developmental deviance to dopamine dysregulation , 2008, European Neuropsychopharmacology.

[23]  Dan J Stein,et al.  World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia , 2008, Schizophrenia Research.

[24]  M. Harrow,et al.  Factors Involved in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications: A 15-Year Multifollow-Up Study , 2007, The Journal of nervous and mental disease.

[25]  G. Vaillant A 10-year followup of remitting schizophrenics. , 1978, Schizophrenia bulletin.

[26]  A. B. Hollingshead,et al.  Social Class and Mental Illness , 1964 .

[27]  J. Strauss,et al.  The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. , 1987, The American journal of psychiatry.

[28]  Kenneth S. Kendler,et al.  The Dopamine Hypothesis of Schizophrenia: An Historical and Philosophical Analysis , 2011 .

[29]  L. Ciompi,et al.  Psychosocial treatment, antipsychotic postponement, and low‐dose medication strategies in first‐episode psychosis: A review of the literature , 2009 .

[30]  L. Grossman,et al.  Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. , 2005, Schizophrenia bulletin.

[31]  T. McGlashan,et al.  Sustained remission in drug-free schizophrenic patients. , 1987, The American journal of psychiatry.

[32]  Michael F. Green,et al.  Neurocognitive and social cognitive correlates of formal thought disorder in schizophrenia patients , 2006, Schizophrenia Research.

[33]  J. Moncrieff A critique of the dopamine hypothesis of schizophrenia and psychosis. , 2009, Harvard review of psychiatry.

[34]  H. Meltzer,et al.  Outcome in manic disorders. A naturalistic follow-up study. , 1990, Archives of general psychiatry.

[35]  A. St-Hilaire,et al.  Life events and high-trait reactivity together predict psychotic symptom increases in schizophrenia. , 2009, Schizophrenia bulletin.

[36]  Philip Seeman,et al.  The Creation of Psychopharmacology , 2002, Nature Medicine.

[37]  J. Veijola,et al.  A systematic review and meta-analysis of recovery in schizophrenia. , 2013, Schizophrenia bulletin.

[38]  John M. Davis,et al.  Maintenance treatment with antipsychotic drugs for schizophrenia. , 2012, The Cochrane database of systematic reviews.

[39]  R. Murray,et al.  The Myth of Schizophrenia as a Progressive Brain Disease , 2012, Schizophrenia bulletin.

[40]  D. Weinberger,et al.  Remission in schizophrenia: proposed criteria and rationale for consensus. , 2005, The American journal of psychiatry.

[41]  Julie Kreyenbuhl,et al.  Practice guideline for the treatment of patients with schizophrenia , 1997 .

[42]  R Kikinis,et al.  Superior temporal gyrus volume abnormalities and thought disorder in left-handed schizophrenic men. , 1999, The American journal of psychiatry.

[43]  P. McHugh,et al.  Long-term follow-up of patients hospitalized for schizophrenia, 1913 to 1940. , 1997, The Journal of nervous and mental disease.

[44]  M. Harrow,et al.  Schizophrenia Course, Long-Term Outcome, Recovery, and Prognosis , 2010 .

[45]  B. Jones,et al.  Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. , 1980, The American journal of psychiatry.

[46]  Scott J. Russo,et al.  HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity , 2012, Nature Neuroscience.

[47]  Johannes Schwarz,et al.  Psychosis pathways converge via D2High dopamine receptors , 2006, Synapse.

[48]  F. Basset,et al.  Anatomy of an Epidemic – Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America , 2012 .

[49]  D. Jeste,et al.  Neuroleptic withdrawal in schizophrenic patients. A review of the literature. , 1995, Archives of general psychiatry.

[50]  D. Charney,et al.  Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. , 2004, The American journal of psychiatry.

[51]  J. Aaltonen,et al.  The Comprehensive Open-Dialogue Approach in Western Lapland: II. Long-term stability of acute psychosis outcomes in advanced community care , 2011 .

[52]  P. Cohen,et al.  The clinician's illusion. , 1984, Archives of general psychiatry.

[53]  R. Baldessarini,et al.  International consensus study of antipsychotic dosing. , 2010, The American journal of psychiatry.

[54]  R. G. Hunt,et al.  Social Class and Mental Illness , 1959 .

[55]  M. Harrow,et al.  Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study , 2012, Psychological Medicine.

[56]  M. Harrow,et al.  How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. , 2010, Schizophrenia bulletin.

[57]  J. Racoosin,et al.  Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. , 2004, Diabetes care.

[58]  C. Waternaux,et al.  One hundred years of schizophrenia: A meta-analysis of the outcome literature , 1993, Schizophrenia Research.

[59]  E. Zigler,et al.  A developmental approach to adult psychopathology , 1986 .

[60]  Nancy H. Covell,et al.  Mental health system funding of cognitive enhancement interventions for schizophrenia: summary and update of the New York Office of Mental Health expert panel and stakeholder meeting. , 2013, Psychiatric rehabilitation journal.

[61]  K. Kaplan,et al.  Thought Disorder in Schizophrenia: Working Memory and Impaired Context , 2004, The Journal of nervous and mental disease.

[62]  T. McGlashan,et al.  Risk factors for psychosis: impaired social and role functioning. , 2012, Schizophrenia bulletin.

[63]  D. Wiersma,et al.  Guided Discontinuation Versus Maintenance Treatment in Remitted First-Episode Psychosis: Relapse Rates and Functional Outcome , 2007 .

[64]  Nathan Clark Consensus development conference on antipsychotic drugs and obesity and diabetes. , 2004, The Journal of clinical psychiatry.

[65]  P. Seeman,et al.  Is schizophrenia a dopamine supersensitivity psychotic reaction? , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[66]  Fredrick C. Redlich,et al.  Social class and mental illness: Community study. , 1958 .

[67]  North American Association for the Study of Obesity , 1991, International journal of obesity.

[68]  D. Kelly,et al.  The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements , 2012 .